Bio IT World | 2bPrecise and The Innovation Institute to Deliver Robust Pharmacogenomics Platform, GeneFolio, to the Point of Care

By Staff | March 7, 2018
Actionable insights to be delivered within providers' workflow for exceptional genomic and clinical care for patients.

HIMSS 2018 - LAS VEGAS - March 7, 2018 - 2bPrecise®, LLC, and The Innovation Institute announced today that they have entered into an agreement that lays the foundation for 2bPrecise to deliver a pharmacogenomics knowledge base to the point of care for The Innovation Institute’s network of member providers, as well as others beyond the network.

The Innovation Institute, a for-profit limited liability company established in 2013 and based in La Palma, Calif., is comprised of six “member owner” health systems - one of which, Avera Health, developed GeneFolio®, a robust drug-drug-gene test and knowledge base, which incorporates pharmacist-based expertise into every test result. The agreement with 2bPrecise, which offers an industry-leading precision medicine platform, is intended to enable GeneFolio to be accessed within the provider workflow across all Innovation Institute health systems, as well as others.

GeneFolio was launched within the Avera footprint in the summer of 2017. “Pharmacogenomics is poised for rapid health care adoption to improve treatment success and Avera has been developing and advancing the integration for almost a decade,” said Krista Bohlen, PharmD, Director of Personalized Medicine at the Avera Institute for Human Genetics. “We’'re excited to offer this test, developed by Avera scientists, laboratory personnel and pharmacists that will serve as a guide for a patient’s care for decades to come.”

GeneFolio draws upon results from a simple saliva or blood sample. GeneFolio tests multiple genes that impact medications in three main classes: pain, depression and other psychiatric disorders, and statins for cholesterol and certain types of blood thinners, with others in development.

Priced affordably, GeneFolio results are delivered in a color-coded report that shows which medications will be metabolized well by the patient, and which should be used with caution or not used at all. The GeneFolio test can be taken once and then results can be consulted for years to come as other medications are prescribed. More...

Posted in In the News